FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215057584> ?p ?o ?g. }

• W3215057584 endingPage "179" @default.
• W3215057584 startingPage "168" @default.
• W3215057584 abstract "BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is associated with substantial clinical burden as individuals transition to adulthood, including higher rates of comorbidities, mortality, incarceration, and psychiatric hospitalizations than in individuals without ADHD. These higher rates likely contribute to substantial economic burden as well. OBJECTIVE: To provide a comprehensive evaluation of the economic burden associated with ADHD in the US adult population. METHODS: Direct health care costs were obtained by using claims data from the IBM MarketScan Research Databases (January 1, 2017, through December 31, 2018). Direct non-health care costs and indirect costs were estimated on the basis of the literature and government publications. Excess costs incurred by adults with ADHD during 2018 were evaluated from a societal perspective; per-patient costs were extrapolated to the national level. RESULTS: An estimated 8.7 million adults live with ADHD in the United States, resulting in a total societal excess cost attributable to ADHD of $122.8 billion ($14,092 per adult). Excess costs of unemployment ($66.8 billion; 54.4%) comprised the largest proportion of the total, followed by productivity loss ($28.8 billion; 23.4%) and health care services ($14.3 billion; 11.6%). CONCLUSIONS: ADHD in adults is associated with substantial economic burden. DISCLOSURES: This study was funded by Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka). The study sponsor contributed to and approved the study design, participated in the interpretation of data, and reviewed and approved the manuscript. Schein is an employee of Otsuka. Gagnon-Sanschagrin, Davidson, Kinkead, Cloutier, Guérin, and Lefebvre are employees of Analysis Group, Inc., a consulting company that provided paid consulting services to Otsuka to develop and conduct this study and write the manuscript. Adler has received research support from Shire/Takeda, Sunovion, and Otsuka; consulting fees from Bracket, Shire/Takeda, Sunovion, Otsuka, the State University of New York (SUNY), the National Football League (NFL), and Major League Baseball (MLB); and royalty payments (as inventor) from New York University (NYU) for license of adult ADHD scales and training materials. Childress has received research support from Allergan, Takeda/Shire, Emalex, Akili, Ironshore, Arbor, Aevi Genomic Medicine, Neos Therapeutics, Otsuka, Pfizer, Purdue, Rhodes, Sunovion, Tris, KemPharm, Supernus, and the US Food and Drug Administration; was on the advisory board of Takeda/Shire, Akili, Arbor, Cingulate, Ironshore, Neos Therapeutics, Otsuka, Pfizer, Purdue, Adlon, Rhodes, Sunovion, Tris, Supernus, and Corium; received consulting fees from Arbor, Ironshore, Neos Therapeutics, Purdue, Rhodes, Sunovion, Tris, KemPharm, Supernus, Corium, Jazz, and Tulex Pharma; received speaker fees from Takeda/Shire, Arbor, Ironshore, Neos Therapeutics, Pfizer, Tris, and Supernus; and received writing support from Takeda/Shire, Arbor, Ironshore, Neos Therapeutics, Pfizer, Purdue, Rhodes, Sunovion, and Tris. Part of the material in this study was presented as a poster at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 Virtual Meeting; May 17-20, 2021." @default.
• W3215057584 created "2021-12-06" @default.
• W3215057584 creator A5004841700 @default.
• W3215057584 creator A5010701317 @default.
• W3215057584 creator A5012212211 @default.
• W3215057584 creator A5013167675 @default.
• W3215057584 creator A5019269759 @default.
• W3215057584 creator A5024208230 @default.
• W3215057584 creator A5041026389 @default.
• W3215057584 creator A5062639951 @default.
• W3215057584 creator A5065430423 @default.
• W3215057584 date "2022-02-01" @default.
• W3215057584 modified "2023-09-26" @default.
• W3215057584 title "Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective" @default.
• W3215057584 cites W1922973259 @default.
• W3215057584 cites W1946500082 @default.
• W3215057584 cites W1969060266 @default.
• W3215057584 cites W1970966565 @default.
• W3215057584 cites W1971968639 @default.
• W3215057584 cites W1979919601 @default.
• W3215057584 cites W1989648183 @default.
• W3215057584 cites W1995827789 @default.
• W3215057584 cites W2013986318 @default.
• W3215057584 cites W2020344785 @default.
• W3215057584 cites W2033377029 @default.
• W3215057584 cites W2037665165 @default.
• W3215057584 cites W2038732840 @default.
• W3215057584 cites W2040461057 @default.
• W3215057584 cites W2042929391 @default.
• W3215057584 cites W2055913921 @default.
• W3215057584 cites W2058562698 @default.
• W3215057584 cites W2082068049 @default.
• W3215057584 cites W2087925710 @default.
• W3215057584 cites W2093839933 @default.
• W3215057584 cites W2094590423 @default.
• W3215057584 cites W2095439030 @default.
• W3215057584 cites W2104018921 @default.
• W3215057584 cites W2108802679 @default.
• W3215057584 cites W2111117333 @default.
• W3215057584 cites W2112374643 @default.
• W3215057584 cites W2120831849 @default.
• W3215057584 cites W2131099228 @default.
• W3215057584 cites W2140070419 @default.
• W3215057584 cites W2141693119 @default.
• W3215057584 cites W2148991048 @default.
• W3215057584 cites W2154077719 @default.
• W3215057584 cites W2193488777 @default.
• W3215057584 cites W2331034838 @default.
• W3215057584 cites W2523895758 @default.
• W3215057584 cites W2555957564 @default.
• W3215057584 cites W2605689072 @default.
• W3215057584 cites W2746340968 @default.
• W3215057584 cites W2756281492 @default.
• W3215057584 cites W2765813330 @default.
• W3215057584 cites W2782165716 @default.
• W3215057584 cites W2792496846 @default.
• W3215057584 cites W2901798356 @default.
• W3215057584 cites W2902605707 @default.
• W3215057584 cites W29556339 @default.
• W3215057584 cites W2962782260 @default.
• W3215057584 cites W2979385261 @default.
• W3215057584 cites W3087392592 @default.
• W3215057584 cites W3128762795 @default.
• W3215057584 cites W4210997646 @default.
• W3215057584 cites W4211094461 @default.
• W3215057584 cites W4236486344 @default.
• W3215057584 cites W74971179 @default.
• W3215057584 doi "https://doi.org/10.18553/jmcp.2021.21290" @default.
• W3215057584 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34806909" @default.
• W3215057584 hasPublicationYear "2022" @default.
• W3215057584 type Work @default.
• W3215057584 sameAs 3215057584 @default.
• W3215057584 citedByCount "3" @default.
• W3215057584 countsByYear W32150575842022 @default.
• W3215057584 countsByYear W32150575842023 @default.
• W3215057584 crossrefType "journal-article" @default.
• W3215057584 hasAuthorship W3215057584A5004841700 @default.
• W3215057584 hasAuthorship W3215057584A5010701317 @default.
• W3215057584 hasAuthorship W3215057584A5012212211 @default.
• W3215057584 hasAuthorship W3215057584A5013167675 @default.
• W3215057584 hasAuthorship W3215057584A5019269759 @default.
• W3215057584 hasAuthorship W3215057584A5024208230 @default.
• W3215057584 hasAuthorship W3215057584A5041026389 @default.
• W3215057584 hasAuthorship W3215057584A5062639951 @default.
• W3215057584 hasAuthorship W3215057584A5065430423 @default.
• W3215057584 hasConcept C118552586 @default.
• W3215057584 hasConcept C121955636 @default.
• W3215057584 hasConcept C133425853 @default.
• W3215057584 hasConcept C138816342 @default.
• W3215057584 hasConcept C138885662 @default.
• W3215057584 hasConcept C139719470 @default.
• W3215057584 hasConcept C144024400 @default.
• W3215057584 hasConcept C144133560 @default.
• W3215057584 hasConcept C145096142 @default.
• W3215057584 hasConcept C149923435 @default.
• W3215057584 hasConcept C159110408 @default.
• W3215057584 hasConcept C160735492 @default.
• W3215057584 hasConcept C162324750 @default.

• next